|
|
Marketing Authorisations
|
|
|
|
|
Attractive, but close monitoring required
|
|
|
|
|
|
|
|
|
|
|
|
Remain on the market in France and Europe, despite cutaneous adverse effects
|
|
|
|
|
|
|
|
|
|
No benefit despite statistical manipulation
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Avoid using for mild regurgitation
|
|
|
|
|
|
|
|
|
|
Weight loss, potentially fatal aspiration pneumonia
|
|
|
|
|
|
|
|
|
|
Further undermines its role in type 2 diabetes
|
|
|
|
|
|
|
|
|
|
Precautions are required in patients at risk
|
|
|
|
Reviews
|
|
|
|
|
Inform psychologically vulnerable patients of the risk of serious, dose-dependent disorders
|
|
|
|
Outlook
|
|
|
|
|
Lower diagnostic thresholds and medicalisation of life
|
|
|
|
|
|
|
|
|
|
Off-label promotion: shifting a balance of power that benefits industry
|
|
|
|
|
|
|
|
|
|
|
|
About the benfluorex scandal in France
|
|
|
|
|
|
|
|